Your session is about to expire
← Back to Search
Belatacept Injection for Kidney Transplant
Study Summary
This trial will test whether belatacept, when given with a proteasome inhibitor, can help highly HLA sensitized kidney transplant candidates find an acceptable donor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are currently on the waiting list for a kidney transplant at the University of Chicago Transplant Institute.My liver is severely damaged or not functioning well.I have been fully vaccinated against COVID-19 for at least 2 weeks.I have antibodies against the Epstein-Barr Virus.I have not received a live vaccine in the last 4 weeks.I do not have any ongoing infections.I haven't had any cancer except for skin cancer in the last 2 years.I haven't had a heart attack in the last 6 months and my heart condition is stable.I have a previous kidney transplant.You have a very high level of antibodies against potential donor kidneys and are waiting for a kidney transplant at the University of Chicago's kidney transplant program.I am currently pregnant or breastfeeding.I have severe nerve pain or damage.I agree to use two forms of birth control for 3 months after my last Bortezomib dose.I have had PTLD after a transplant.You have been vaccinated against hepatitis B and have a positive level of HBsAb.I have untreated latent TB.
- Group 1: Patients treated with belatacept and proteasome inhibitor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients currently being enrolled in this particular clinical trial?
"According to the latest update on clinicaltrials.gov, this research is actively recruiting subjects. The trial was initially advertised on May 1st, 2020 and has since been updated 13 days ago."
How many people are eligible to participate in this clinical trial?
"That is correct. The listing on clinicaltrials.gov says that the trial is still open and looking for candidates. This study was first posted on May 1st, 2022 and received its most recent update on May 13th, 2022. So far, only 5 people have been recruited from a single site."
What are the inclusionary criteria for this trial?
"This study has 5 open slots for participants that fit the following description: experiencing chronic kidney failure, aged 18-60, and vaccinated against hepatitis b with positive HBsAb levels. Additionally, candidates must be EBV IgG seropositive and actively listed for transplant at the University of Chicago's Transplant Institute. There can be no active systemic infection, malignancy in the past 2 years (with exception of non-melanomatous skin cancer), or allergies to belatacept or proteasome inhibitors. Finally, this study is only for female patients who agree to use 2 forms of contraception for 3 months after"
Are elderly patients above the age of 75 eligible to participate in this clinical trial?
"This trial is only seeking patients that fall in the age bracket of 18 to 60 years old. Out of the 639 total trials, 63 are for minors and 639 are for senior citizens."
Share this study with friends
Copy Link
Messenger